S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$106.56
-4.03 (-3.64%)
(As of 03/28/2024 ET)
Today's Range
$105.95
$112.00
50-Day Range
$85.37
$111.98
52-Week Range
$62.55
$163.24
Volume
3.96 million shs
Average Volume
4.41 million shs
Market Capitalization
$40.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$129.82

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
21.8% Upside
$129.82 Price Target
Short Interest
Bearish
6.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.47mentions of Moderna in the last 14 days
Based on 39 Articles This Week
Insider Trading
Selling Shares
$5.21 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.48) to ($5.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

326th out of 938 stocks

Biological Products, Except Diagnostic Industry

47th out of 154 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

How you can target big results without spending big money!
While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades!
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CARsgen Announced 2023 Annual Results
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
5,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$129.82
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+21.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
16 Analysts

Profitability

Net Income
$-4,714,000,000.00
Pretax Margin
-57.56%

Debt

Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
322,768,000
Market Cap
$41.03 billion
Optionable
Optionable
Beta
1.60

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Moderna was last updated on Monday, March 25, 2024 at 11:51 PM.

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. is a leading biotechnology company that focuses on developing messenger RNA therapeutics and vaccines for various diseases, including COVID-19.
  • The company has a diverse pipeline of products targeting infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.
  • Moderna has strategic alliances and collaborations with major pharmaceutical companies like AstraZeneca and Merck & Co., Inc., which can enhance its research and development capabilities.
  • Recent positive clinical trial results and regulatory approvals for its vaccines have boosted investor confidence in the company's growth potential.
  • Despite fluctuations, Moderna's stock price has shown resilience and potential for growth, making it an attractive investment option in the biotechnology sector.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Biotechnology investments can be volatile due to regulatory uncertainties, clinical trial outcomes, and competition from other companies in the industry.
  • Moderna's success heavily relies on the continued efficacy of its mRNA technology, which may face challenges or limitations in the future.
  • Market fluctuations and investor sentiment towards healthcare and biotechnology stocks can impact Moderna's stock price unpredictably.
  • The biotechnology sector is highly competitive, and Moderna faces competition from established players and emerging biotech firms in the development of mRNA therapeutics and vaccines.
  • Investors need to carefully monitor regulatory developments, intellectual property issues, and market trends that could affect Moderna's long-term growth prospects and stock performance.

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

16 Wall Street research analysts have issued 1 year price objectives for Moderna's shares. Their MRNA share price targets range from $60.00 to $231.00. On average, they predict the company's share price to reach $129.82 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 on January 1st, 2024. Since then, MRNA shares have increased by 7.1% and is now trading at $106.56.
View the best growth stocks for 2024 here
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, February, 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. The firm earned $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative trailing twelve-month return on equity of 10.23% and a negative net margin of 68.84%. Moderna's quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.61 EPS.

What guidance has Moderna issued on next quarter's earnings?

Moderna issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.97%), Vanguard Group Inc. (8.89%), Vanguard Group Inc. (8.87%), Wellington Management Group LLP (1.89%), Capital World Investors (0.95%) and The Manufacturers Life Insurance Company (0.93%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners